Metformin in Safety and Efficacy in Gouty Patients
Key facts
- Who runs it
- Mostafa Bahaa
- Where
- Egypt1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 70 people, planned
- Started
- 20 Apr 2025
- Expected to end
- 20 Nov 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- placebo
- Metformin
- Record updated
- 30 September 2026
Who can take part
- Age
- 18 years to 60 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Gouty patients clinically diagnosed as gouty arthritis based on the American College of Rheumatology/European League Against Rheumatism criteria of gout
Who cannot take part
- Systemic disorders such as cardiovascular, neurological, coronary artery disease
- Hypertension, hyperlipidemia, diabetes mellitus, active infections
- Other inflammatory or autoimmune diseases
- Cases with hypersensitivity to metformin and those with impaired liver and kidney functions
- Patients on biologics,
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 60 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The most frequent crystal arthropathy is gout, which is also the most prevalent cause of inflammatory arthritis. Gouty Patients frequently have excruciating pain and swelling in their joints. Gout is linked to decreased health-related quality of life and functional disability. Gout and its associated diseases have been shown to have a significant impact on patients mortality and morbidities. Metformin, a biguanide, is used to manage diabetes by reducing insulin resistance and preventing comorbidities such as cerebrovascular and coronary artery disease, as well as providing renal protection to diabetic nephropathy patients
The 2 groups in the trial
- Control groupExisting treatment, for comparison
this group will receive placebo in addition to the traditional lines of treatment of gout.
Treatment: placebo
- Metformin groupExisting treatment, for comparison
This group will receive metformin (1000mg/day) in addition to the traditional lines of treatment of gout.
Treatment: Metformin
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- the Impact of Metformin Use on Clinical Outcomes in Gouty Patients
- Fit questions
- Built from NCT06924658, who can take part
- Record updated
- 30 September 2026